Home2020/06 June 2, 2020 -

https://mysicklefamilyllc.com/wp-content/uploads/2020/06/shutterstock_522145906_zpsbrn8jkwk.jpg

IMR-687 safely increases the levels of fetal hemoglobin and the number of fetal hemoglobin-producing cells in people with sickle cell disease (SCD), according to early data from an ongoing Phase 2a clinical trial. The findings support the continuation of IMR-687’s clinical development as a potential disease modifying therapy for SCD, investigators said. Results will be shared in an oral presentation titled, “IMR-687, A Highly Selective Phosphodiesterase 9 Inhibitor (PDE9I), Increases F-Cells and Fetal Hemoglobin in...